- FDA analysis finds no new or unexpected safety risks associated
with NUPLAZID
- Patients taking NUPLAZID for Parkinson’s
disease psychosis should continue to use it as prescribed by their
health care provider
- FDA also reminds health care providers
that no other antipsychotic medication is approved for the treatment of
Parkinson’s disease psychosis
SAN DIEGO—(BUSINESS WIRE)—Sep. 20, 2018—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that the FDA
has completed a postmarketing review and issued a clear statement
reaffirming the positive benefit-risk profile of NUPLAZID (pimavanserin)
for patients with Parkinson’s disease psychosis. NUPLAZID is the only
medicine approved in the United States to treat hallucinations and
delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID
was approved by the FDA based on a pivotal Phase 3 study that
demonstrated clinically robust and highly statistically significant
efficacy, combined with other supportive studies.
Following the FDA’s review, the FDA concluded, “The U.S. FDA has
completed a review of all postmarketing reports of deaths and serious
adverse events (SAEs) reported with the use of NUPLAZID. Based on an
analysis of all available data, FDA did not identify any new or
unexpected safety findings with NUPLAZID, or findings that are
inconsistent with the established safety profile currently described in
the drug label. After a thorough review, FDA’s conclusion remains
unchanged that the drug’s benefits outweigh its risks for patients with
hallucinations and delusions of Parkinson’s disease psychosis.” In
addition, the FDA stated that, “patients taking NUPLAZID for Parkinson’s
disease psychosis should continue to use it as prescribed by their
health care providers. Based on this observation, FDA reminds health
care providers to be aware of the risks described in the prescribing
information. FDA also reminds health care providers that none of the
other antipsychotic medications are approved for the treatment of
Parkinson’s disease psychosis.”
“Nothing is more important to ACADIA than the wellbeing of the patients
who use NUPLAZID. We are very pleased with the FDA’s clear statement
reaffirming NUPLAZID’s positive benefit-risk profile,” said Steve Davis,
ACADIA’s President and Chief Executive Officer. “We are also pleased
with the FDA’s conclusion that patients taking NUPLAZID for Parkinson’s
disease psychosis should continue to use it as prescribed by their
health care provider and its reminder that no other antipsychotic
medication is approved for the treatment of PDP.”
FDA Full Statement
FDA analysis finds no new or unexpected safety risks associated with
NUPLAZID (pimavanserin), a medication to treat the hallucinations and
delusions of Parkinson’s disease psychosis (Link)
Health care providers reminded to follow prescribing information
[09-20-2018] The U.S. Food and Drug Administration (FDA) has completed a
review of all postmarketing reports of deaths and serious adverse events
(SAEs) reported with the use of NUPLAZID (pimavanserin). Based on an
analysis of all available data, FDA did not identify any new or
unexpected safety findings with NUPLAZID, or findings that are
inconsistent with the established safety profile currently described in
the drug
label. After a thorough review, FDA’s conclusion remains unchanged
that the drug’s benefits outweigh its risks for patients with
hallucinations and delusions of Parkinson’s disease psychosis.
NUPLAZID and other antipsychotics have a Boxed Warning regarding the
increased risk of death in elderly patients with dementia-related
psychosis associated with the use of these drugs. In view of the numbers
of reports of death and other serious adverse events, FDA conducted a
comprehensive analysis of all available information. This analysis
included information submitted to the FDA Adverse Event Reporting System
(FAERS), drug utilization data, safety data from the NUPLAZID new drug
application, the sponsor’s Periodic Adverse Drug Experience Reports, the
sponsor’s analysis of fatal adverse event reports with NUPLAZID and
published medical literature.
In assessing the reports of deaths, FDA considered that patients with
Parkinson’s disease psychosis, for whom NUPLAZID is indicated, have a
higher mortality (death) rate due to their older age, advanced
Parkinson’s disease, and other medical conditions. Moreover, NUPLAZID is
primarily distributed through a patient support program and a specialty
pharmacy network, which increases the likelihood that deaths will be
reported to the manufacturer. In FAERS reports that included a cause of
death (many reports did not provide sufficient information to assess
drug cause and effect), there was no evident pattern to suggest a drug
effect. Overall, the postmarketing data were consistent with the safety
data obtained from the premarketing controlled clinical trials of
NUPLAZID for Parkinson’s disease psychosis.
Although FDA did not identify any new or unexpected safety risks, some
potentially concerning prescribing patterns were observed, such as the
concomitant use of other antipsychotic drugs or drugs that can cause QT
prolongation, a potential cause of heart rhythm disorder. The risk of QT
prolongation and serious arrhythmia (abnormal heart rhythm) associated
with NUPLAZID is noted in the Warnings and Precautions section of the
drug label, which warns of the increased risks associated with using
NUPLAZID together with other drugs known to cause QT interval
prolongation. Based on this observation, FDA reminds health care
providers to be aware of the risks described in the prescribing
information. FDA also reminds health care providers that none of the
other antipsychotic medications are approved for the treatment of
Parkinson’s disease psychosis.
Patients taking NUPLAZID for Parkinson’s disease psychosis should
continue to use it as prescribed by their health care provider. FDA
continues to monitor reports of adverse events associated with NUPLAZID.
The agency will communicate any updates to the public as necessary. To
help FDA assess potential medication safety issues, we urge health care
providers and patients to report suspected side effects involving
NUPLAZID and other drugs to the FDA
MedWatch program.
End of FDA Full Statement
About Parkinson’s Disease Psychosis
According to the
Parkinson’s Foundation, about one million people in the United States
and from four to six million people worldwide suffer from Parkinson’s
disease. More than 50 percent of people with Parkinson’s will experience
symptoms of psychosis over the course of their disease. PD Psychosis is
characterized by hallucinations and delusions, is associated with
significant caregiver burden, and is a major reason for nursing home
placement among Parkinson’s patients.
About NUPLAZID® (pimavanserin)
NUPLAZID
is the first FDA-approved treatment for hallucinations and delusions
associated with Parkinson’s disease psychosis. NUPLAZID is a
non-dopaminergic, selective serotonin inverse agonist preferentially
targeting 5-HT2A receptors that are thought to play an
important role in Parkinson’s disease psychosis. NUPLAZID is an oral
medicine taken once a day with a recommended dose of 34 mg. ACADIA
discovered and developed this new chemical entity and holds worldwide
rights to develop and commercialize NUPLAZID.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical
company focused on the development and commercialization of innovative
medicines to address unmet medical needs in central nervous system
disorders. ACADIA has developed and is commercializing the first and
only medicine approved for the treatment of hallucinations and delusions
associated with Parkinson’s disease psychosis. In addition, ACADIA has
ongoing clinical development efforts in additional areas with
significant unmet need, including dementia-related psychosis,
schizophrenia inadequate response, schizophrenia-negative symptoms,
major depressive disorder and Rett syndrome. This press release and
further information about ACADIA can be found at: www.acadia-pharm.com.
Forward-Looking Statements
Statements in this press release
that are not strictly historical in nature are forward-looking
statements. These statements include but are not limited to statements
related to the benefits to be derived from NUPLAZID. These statements
are only predictions based on current information and expectations and
involve a number of risks and uncertainties. Actual events or results
may differ materially from those projected in any of such statements due
to various factors, including the risks and uncertainties inherent in
drug discovery, development, approval and commercialization, and the
fact that past results of clinical trials may not be indicative of
future trial results. For a discussion of these and other factors,
please refer to ACADIA’s annual report on Form 10-K for the year ended
December 31, 2017 as well as ACADIA’s subsequent filings with the
Securities and Exchange Commission. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date hereof. This caution is made under the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. All
forward-looking statements are qualified in their entirety by this
cautionary statement and ACADIA undertakes no obligation to revise or
update this press release to reflect events or circumstances after the
date hereof, except as required by law.
Important Safety Information and Indication for
NUPLAZID (pimavanserin)
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH
DEMENTIA-RELATED PSYCHOSIS
Elderly patients with
dementia-related psychosis treated with antipsychotic drugs are at an
increased risk of death. NUPLAZID is not approved for the treatment of
patients with dementia-related psychosis unrelated to the hallucinations
and delusions associated with Parkinson’s disease psychosis.
NUPLAZID is an atypical antipsychotic indicated for the treatment of
hallucinations and delusions associated with Parkinson’s disease
psychosis.
Contraindication: NUPLAZID is contraindicated in patients with a history
of a hypersensitivity reaction to pimavanserin or any of its components.
Rash, urticaria, and reactions consistent with angioedema (e.g., tongue
swelling, circumoral edema, throat tightness, and dyspnea) have been
reported.
QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of
NUPLAZID should be avoided in patients with known QT prolongation or in
combination with other drugs known to prolong QT interval including
Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain
antipsychotic medications, and certain antibiotics. NUPLAZID should also
be avoided in patients with a history of cardiac arrhythmias, as well as
other circumstances that may increase the risk of the occurrence of
torsade de pointes and/or sudden death, including symptomatic
bradycardia, hypokalemia or hypomagnesemia, and presence of congenital
prolongation of the QT interval.
Adverse Reactions: The most common adverse reactions (≥2% for NUPLAZID
and greater than placebo) were peripheral edema (7% vs 2%), nausea (7%
vs 4%), confusional state (6% vs 3%), hallucination (5% vs 3%),
constipation (4% vs 3%), and gait disturbance (2% vs <1%).
Drug Interactions: Coadministration with strong CYP3A4 inhibitors (e.g.,
ketoconazole) increases NUPLAZID exposure. Reduce NUPLAZID dose to 10 mg
taken orally as one tablet once daily. Coadministration with strong
CYP3A4 inducers may reduce NUPLAZID exposure. Monitor patients for
reduced efficacy and an increase in NUPLAZID dosage may be needed.
Pediatric Use: Safety and efficacy have not been established in
pediatric patients.
Dosage and Administration: Recommended dose: 34 mg taken orally once
daily, without titration.
NUPLAZID is available as 34 mg capsules, 17 mg tablets and 10 mg tablets.
For additional Important Safety Information, including Boxed WARNING,
please see the full Prescribing Information for NUPLAZID at https://www.NUPLAZID.com/pdf/NUPLAZID_Prescribing_Information.pdf.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180920005948/en/
Source: ACADIA Pharmaceuticals Inc.
Investor Contact:
ACADIA Pharmaceuticals Inc.
Elena
Ridloff, CFA
(858) 558-2871
[email protected]
or
Media
Contact:
Taft Communications
Bob Laverty
(609)
558-5570
[email protected]